Nonsteroidal anti-inflammatory drugs and cardiovascular disease risk in spondyloarthritis-spectrum diseases. Issue 4 (July 2022)

• Record Type: Journal Article
• Authors: So, Ho; Tam, Lai-Shan
• Is Part Of: Current opinion in rheumatology. Volume 34:Issue 4(2022)
• Page Start: 203
• Page End: 208
• Publication Date: 2022-07
• Subjects: cardiovascular disease -- nonsteroidal anti-inflammatory drugs -- psoriatic arthritis -- spondyloarthritis; Rheumatology -- Periodicals; Arthritis -- Periodicals; Review Literature -- Periodicals; Rheumatic Diseases -- Periodicals; 616.723
• DOI: 10.1097/BOR.0000000000000881
• Languages: English
• ISSNs: 1040-8711

Abstract

Abstract : Purpose of review: Increased cardiovascular (CV) risk associated with nonsteroidal anti-inflammatory drugs (NSAIDs) is well recognized in the general population. This may limit the use of this effective therapy in patients with spondyloarthritis (SpA), a population already at high CV risk. Recent findings: Increased CV diseases and their risk factors in patients with SpA were consistently shown in recent population-level data. NSAIDs remained commonly prescribed in SpA, though their structural benefit remained controversial and the dispensing practice was variable in different regions in the world. A previous observation study suggested NSAIDs in SpA might be cardio-protective, possibly via their modulation of the chronic inflammatory state. A recent meta-analysis of nonrandomized studies also revealed no increased risk of a CV event. Interestingly, there is growing evidence that different NSAIDs might impose differential CV risk on patients with SpA. Summary: Recent evidence suggested NSAIDs were associated with a neutral and possibly lower CV risk in patients with SpA, which provided some reassurance for their use.